JP2018512155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512155A5 JP2018512155A5 JP2017553347A JP2017553347A JP2018512155A5 JP 2018512155 A5 JP2018512155 A5 JP 2018512155A5 JP 2017553347 A JP2017553347 A JP 2017553347A JP 2017553347 A JP2017553347 A JP 2017553347A JP 2018512155 A5 JP2018512155 A5 JP 2018512155A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide
- dsrna
- nucleotides
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 43
- 239000002773 nucleotide Substances 0.000 claims 32
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 12
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 9
- 108091081021 Sense strand Proteins 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 208000035762 Disorder of lipid metabolism Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-Anhydro-mannit Natural products OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims 1
- UEUPTUCWIHOIMK-UHFFFAOYSA-N 2'-deoxy-AMP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(OP(O)(O)=O)C(CO)O1 UEUPTUCWIHOIMK-UHFFFAOYSA-N 0.000 claims 1
- UEUPTUCWIHOIMK-RRKCRQDMSA-N 2'-deoxyadenosine 3'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](OP(O)(O)=O)[C@@H](CO)O1 UEUPTUCWIHOIMK-RRKCRQDMSA-N 0.000 claims 1
- QQMSZHORHNORLP-KVQBGUIXSA-N 2'-deoxyguanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](OP(O)(O)=O)[C@@H](CO)O1 QQMSZHORHNORLP-KVQBGUIXSA-N 0.000 claims 1
- QQMSZHORHNORLP-UHFFFAOYSA-N 2'-deoxyguanosine 3'-monophosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(OP(O)(O)=O)C(CO)O1 QQMSZHORHNORLP-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical group N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- ONKSSDKXDIVIHK-UHFFFAOYSA-N n,n-didecyldodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC ONKSSDKXDIVIHK-UHFFFAOYSA-N 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- -1 thymidine-glycol nucleic acid Chemical class 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147698A JP2022002518A (ja) | 2015-04-13 | 2021-09-10 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
| JP2023169168A JP2024009838A (ja) | 2015-04-13 | 2023-09-29 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146604P | 2015-04-13 | 2015-04-13 | |
| US62/146,604 | 2015-04-13 | ||
| US201562261361P | 2015-12-01 | 2015-12-01 | |
| US62/261,361 | 2015-12-01 | ||
| PCT/US2016/027271 WO2016168286A1 (en) | 2015-04-13 | 2016-04-13 | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147698A Division JP2022002518A (ja) | 2015-04-13 | 2021-09-10 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512155A JP2018512155A (ja) | 2018-05-17 |
| JP2018512155A5 true JP2018512155A5 (cg-RX-API-DMAC7.html) | 2019-05-23 |
| JP6975641B2 JP6975641B2 (ja) | 2021-12-01 |
Family
ID=55806850
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553347A Active JP6975641B2 (ja) | 2015-04-13 | 2016-04-13 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
| JP2021147698A Pending JP2022002518A (ja) | 2015-04-13 | 2021-09-10 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
| JP2023169168A Pending JP2024009838A (ja) | 2015-04-13 | 2023-09-29 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147698A Pending JP2022002518A (ja) | 2015-04-13 | 2021-09-10 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
| JP2023169168A Pending JP2024009838A (ja) | 2015-04-13 | 2023-09-29 | アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10570393B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283631A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6975641B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102749152B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115927335A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016247922B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017021053A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2982450A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201792263A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL254786B (cg-RX-API-DMAC7.html) |
| MX (2) | MX392757B (cg-RX-API-DMAC7.html) |
| TW (3) | TWI862799B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168286A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2839573A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| TWI862799B (zh) | 2015-04-13 | 2024-11-21 | 美商阿尼拉製藥公司 | 類血管生成素3(ANGPTL3)iRNA組成物及其用途方法 |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| JP7273417B2 (ja) | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP7727308B2 (ja) * | 2017-12-01 | 2025-08-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| DK3732185T3 (da) * | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原(AGT)iRNA組成物及其使用方法 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| US20210388356A1 (en) * | 2018-11-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotide |
| WO2020099482A2 (en) * | 2018-11-13 | 2020-05-22 | Lipigon Pharmaceuticals Ab | Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| WO2021119019A1 (en) * | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
| KR20230011913A (ko) * | 2020-03-04 | 2023-01-25 | 버브 테라퓨틱스, 인크. | 표적화된 rna 전달을 위한 조성물 및 방법 |
| WO2021204872A1 (en) * | 2020-04-07 | 2021-10-14 | Uniqure Ip B.V. | Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof |
| EP4223875A1 (en) * | 2020-09-30 | 2023-08-09 | Nanopeptide (Qingdao) Biotechnology Ltd. | Sirna of angiopoietin-like 3 (angptl3) and use thereof |
| EP4229200A1 (en) * | 2020-10-16 | 2023-08-23 | Sanofi | Novel rna compositions and methods for inhibiting angptl3 |
| CN114685585B (zh) * | 2020-12-31 | 2024-06-04 | 苏州瑞博生物技术股份有限公司 | 核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途 |
| IL305414A (en) * | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them |
| EP4313075A4 (en) * | 2021-03-24 | 2025-06-18 | Atalanta Therapeutics, Inc. | DOUBLE-STRANDED SIRNA WITH PATTERNED CHEMICAL MODIFICATIONS |
| JP2024535852A (ja) * | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ANGPTL4をサイレンシングするためのiRNA組成物および方法 |
| KR20240053627A (ko) * | 2021-09-23 | 2024-04-24 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오포이에틴-유사 3(angptl3) 단백질의 발현을 억제하기 위한 조성물 및 방법 |
| WO2023092102A1 (en) * | 2021-11-19 | 2023-05-25 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof |
| MX2024007900A (es) | 2021-12-22 | 2024-07-10 | Regeneron Pharma | Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3). |
| WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
| CN116987696A (zh) * | 2022-08-04 | 2023-11-03 | 北京福元医药股份有限公司 | 用于抑制angptl3基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
| WO2024032608A1 (zh) * | 2022-08-08 | 2024-02-15 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
| AU2023375521A1 (en) | 2022-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
| WO2024227059A2 (en) * | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| TW202530409A (zh) * | 2023-10-07 | 2025-08-01 | 大陸商齊魯製藥有限公司 | iRNA組合物及其使用方法 |
| WO2025169133A1 (en) | 2024-02-09 | 2025-08-14 | Astrazeneca Ab | Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof |
| WO2025201277A1 (en) * | 2024-03-25 | 2025-10-02 | Shanghai Argo Biopharmaceutical Co., Ltd. | Method for treating dyslipidemia with angiopoietin-like 3 (angptl3) -targeted rnai agents |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| RU2123492C1 (ru) | 1993-02-19 | 1998-12-20 | Ниппон Синяку Ко., Лтд | Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| EP1042280A2 (en) | 1997-12-24 | 2000-10-11 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| BR9914773A (pt) | 1998-10-09 | 2002-02-05 | Ingene Inc | Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica |
| IL142490A0 (en) | 1998-10-09 | 2002-03-10 | Ingene Inc | ENZYMATIC SYNTHESIS OF ssDNA |
| TWI260322B (en) | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| ATE541928T1 (de) | 2005-03-31 | 2012-02-15 | Calando Pharmaceuticals Inc | Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen |
| ZA200904022B (en) | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
| CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
| EP2245039A4 (en) | 2008-01-31 | 2012-06-06 | Alnylam Pharmaceuticals Inc | OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN |
| ES2740129T3 (es) | 2008-09-25 | 2020-02-05 | Alnylam Pharmaceuticals Inc | Composiciones formuladas en lípidos y métodos de inhibición de la expresión del gen de suero amiloide A |
| JP5791505B2 (ja) | 2008-10-20 | 2015-10-07 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | トランスチレチンの発現を阻害するための組成物および方法 |
| WO2010068816A1 (en) | 2008-12-10 | 2010-06-17 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| EP2380108A4 (en) * | 2009-01-20 | 2013-01-23 | Videojet Technologies Inc | DATE PRINTING PROCESS |
| PL2440183T3 (pl) | 2009-06-10 | 2019-01-31 | Arbutus Biopharma Corporation | Ulepszona formulacja lipidowa |
| NZ597504A (en) | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US8481292B2 (en) * | 2010-09-21 | 2013-07-09 | Population Genetics Technologies Litd. | Increasing confidence of allele calls with molecular counting |
| CA2839573A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| IL303831A (en) * | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| WO2013165816A2 (en) * | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| AU2013296321B2 (en) | 2012-08-03 | 2019-05-16 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| CA2879693A1 (en) | 2012-08-06 | 2014-02-13 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated rna agents and process for their preparation |
| TW201515650A (zh) * | 2013-05-06 | 2015-05-01 | 艾爾妮蘭製藥公司 | 遞送經脂質調配之核酸分子之劑量及方法 |
| DK3087183T3 (da) | 2013-12-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Modulation af angiopoietin-3-lignende ekspression |
| US9382540B2 (en) * | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| US20180245077A1 (en) | 2015-03-20 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| TWI862799B (zh) | 2015-04-13 | 2024-11-21 | 美商阿尼拉製藥公司 | 類血管生成素3(ANGPTL3)iRNA組成物及其用途方法 |
| MX2020001912A (es) | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| JOP20210142A1 (ar) | 2018-12-10 | 2023-01-30 | Amgen Inc | تركيبات rnai لتثبيط التعبير الوراثي عن pnpla3 وطرق استخدامها |
| EP4045062A1 (en) | 2019-10-14 | 2022-08-24 | Astrazeneca AB | Modulators of pnpla3 expression |
| AU2021236674B2 (en) | 2020-03-18 | 2025-03-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ANGPTL3 expression |
| US20230357768A1 (en) | 2020-09-17 | 2023-11-09 | Astrazeneca Ab | Pharmaceutical compositions comprising an antisense oligonucleotide for oral administration |
| IL305414A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them |
| AU2022298603A1 (en) | 2021-06-21 | 2024-02-01 | Shanghai Junshi Biosciences Co., Ltd. | Sirna inhibiting angptl3 gene expression, and use thereof |
| CN120112639A (zh) | 2022-08-22 | 2025-06-06 | 箭头药业股份有限公司 | Angptl3相关疾病和病症的治疗方法 |
| WO2024164008A1 (en) | 2023-02-03 | 2024-08-08 | Sirnaomics, Inc. | Products and compositions |
| US20250051771A1 (en) | 2023-07-24 | 2025-02-13 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
-
2016
- 2016-04-13 TW TW110107949A patent/TWI862799B/zh active
- 2016-04-13 IL IL254786A patent/IL254786B/en unknown
- 2016-04-13 JP JP2017553347A patent/JP6975641B2/ja active Active
- 2016-04-13 KR KR1020177032320A patent/KR102749152B1/ko active Active
- 2016-04-13 CN CN202211369371.8A patent/CN115927335A/zh active Pending
- 2016-04-13 CA CA2982450A patent/CA2982450A1/en active Pending
- 2016-04-13 MX MX2017013102A patent/MX392757B/es unknown
- 2016-04-13 EA EA201792263A patent/EA201792263A1/ru unknown
- 2016-04-13 AU AU2016247922A patent/AU2016247922B2/en active Active
- 2016-04-13 CN CN201680034444.4A patent/CN107743522B/zh active Active
- 2016-04-13 IL IL295159A patent/IL295159A/en unknown
- 2016-04-13 TW TW113139390A patent/TW202507005A/zh unknown
- 2016-04-13 TW TW105111464A patent/TWI723986B/zh active
- 2016-04-13 WO PCT/US2016/027271 patent/WO2016168286A1/en not_active Ceased
- 2016-04-13 EP EP16718146.0A patent/EP3283631A1/en active Pending
- 2016-04-13 BR BR112017021053A patent/BR112017021053A2/pt not_active Application Discontinuation
- 2016-04-13 KR KR1020247042979A patent/KR20250005546A/ko active Pending
-
2017
- 2017-10-11 MX MX2022006507A patent/MX2022006507A/es unknown
- 2017-10-12 US US15/782,091 patent/US10570393B2/en active Active
-
2019
- 2019-12-12 US US16/712,152 patent/US11198872B2/en active Active
-
2021
- 2021-09-10 JP JP2021147698A patent/JP2022002518A/ja active Pending
- 2021-11-03 US US17/517,733 patent/US20220119815A1/en not_active Abandoned
-
2022
- 2022-06-29 AU AU2022204634A patent/AU2022204634B2/en active Active
-
2023
- 2023-06-20 US US18/337,495 patent/US12492401B2/en active Active
- 2023-09-29 JP JP2023169168A patent/JP2024009838A/ja active Pending